Abeona Therapeutics faces a pivotal FDA decision after a CRL-led crash and partial rebound in pz-cel’s valuation. Check out ...

The FDA has approved Krystal Biotech’s gene therapy Vyjuvek for dystrophic epidermolysis bullosa (DEB), a rare genetic disease characterised by fragile skin that can split and blister even with ...

Krystal Biotech is a leader in “redosable” gene therapy with its FDA-approved treatment, VYJUVEK, for dystrophic epidermolysis bullosa (DEB). With plans for expansion into the EU and Japan in ...

Gene therapy for cystic fibrosis is advancing fast. Explore key biotech players, clinical progress, and its potential to ...

Krystal Biotech, Jeune's parent company, is a commercial-stage biotechnology firm that has successfully launched VYJUVEK®, the first redosable gene therapy, and FDA-approved treatment for ...

Krystal Biotech, Jeune’s parent company, is a commercial-stage biotechnology firm that has successfully launched VYJUVEK®, the first redosable gene therapy, and FDA-approved treatment for dystrophic ...

Krystal Biotech received a significant boost with the FDA approval of Vyjuvek, the first-ever revocable gene therapy for treating patients, aged six months or older, with dystrophic epidermolysis ...

Analysts at Oppenheimer highlighted their anticipation of the upcoming Prescription Drug User Fee Act (PDUFA ... a smoother path toward potential approval for Abeona’s therapy.

This detail suggests a smoother path toward potential approval ... FDA that addressed Chemistry, Manufacturing, and Controls issues but did not question the product’s safety or efficacy. The presence ...

“I am excited to welcome Marc to the team as we embark on the next stage of growth at Jeune,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech and Chairman of Jeune Aesthetics. “Marc brings ...

The current macro environment appears grim, given the uncertainty around the global trade war, along with ongoing ...